Nearly 30 years ago, certain small, relatively nontoxic peptides were discovered to be capable of traversing the cell membrane. These cell-penetrating peptides, as they are now called, have been shown to not only be capable of crossing the cell membrane themselves but can also carry many different therapeutic agents into cells, including small molecules, plasmid DNA, siRNA, therapeutic proteins, viruses, imaging agents, and other various nanoparticles. Many cellpenetrating peptides have been derived from natural proteins, but several other cell-penetrating peptides have been developed that are either chimeric or completely synthetic. How cellpenetrating peptides are internalized into cells has been a topic of debate, with some peptides seemingly entering cells through an endocytic mechanism and others by directly penetrating the cell membrane. Although the entry mechanism is still not entirely understood, it seems to be dependent on the peptide type, the peptide concentration, the cargo the peptide transports, and the cell type tested. With new intracellular disease targets being discovered, cell-penetrating peptides offer an exciting approach for delivering drugs to these intracellular targets. There are hundreds of cell-penetrating peptides being studied for drug delivery, and ongoing studies are demonstrating their success both in vitro and in vivo.
TAT trans-activator protein or peptide 8
Introduction 1
Cells are adept at preventing small molecules, proteins, genetic material, and larger protein 2 complexes from entering in a nonspecific manner. The exterior of the cell is composed of a fluid, 3 phospholipid bilayer that is coated with proteoglycans. The lipid bilayer that makes up the cell 4 membrane has a polar surface with a nonpolar interior. Together, the contrasting nature of the 5 membrane lipid bilayer prevents most molecules from passively diffusing directly through the 6 cell membrane. Instead, cells use a combination of ion channels and carrier proteins to transport 7 important molecules such as ions, sugars, and amino acids across the lipid bilayer. Cells also 8 may use endocytosis or exocytosis to transport material in bulk across the membrane. 9
While precise control of transport across the cell membrane is generally advantageous for 10 the cell, many potential therapeutic drug targets are located within the interior of the cell and 11 require entry of pharmaceutical molecules in order to be effectively treated. This has long been a 12 challenge in the field of gene therapy (Khalil et al. 2006) , where a therapeutic gene must not only 13 be transported across the cell membrane, but must also be transported to the nucleus of the cell 14
where it can be transcribed and translated into a therapeutic protein. Similarly, siRNA must also 15 be transported across the cell membrane to the cell cytosol where it can act on the mRNA of the 16 gene being silenced. Likewise, there are a growing number of intracellular targets for cancer 17 therapy. In some cases, cancer treatment may benefit from the intracellular delivery of a 18 particular protein, such as a cytotoxic protein or a tumor suppressor protein that is not natively 19 2014) . Cancer therapy may also benefit from delivery of peptides that act as inhibitors. 21
Examples include peptides that act by preventing STAT3 from binding to DNA in tumor cells 22 (Turkson et al. 2001) , peptides that inhibit angiogenesis by hindering β protein kinase C 23 Synthetic peptides are the final classification group based on the origin of the CPP. Model 1 amphipathic peptide (MAP) and polyarginine are both listed in Table 1 and were two of the first 2 synthetic peptides developed. These early synthetic peptides were designed to mimic CPPs 3 based on natural proteins. For example, polyarginine was investigated for its cell-penetrating 4 ability because of its similarity to TAT, which also has a large number of arginine residues 5 (Wender et al. 2000 , Tünnemann et al. 2008 . MAP was meant to be a model peptide that had 6 amphipathic alpha helical secondary structure, which could be used to study if unique structural 7 features were necessary for membrane passage, as was thought to be the case with the pAntp 8 peptide (Oehlke et al. 1996) . Since the discovery of these two synthetic peptides, and many 9 more like them, molecular cloning techniques and screening tools such as phage display have 10 enabled high-throughput screening of large peptide libraries. These libraries have yielded 11 additional synthetic CPPs that, unlike polyarginine and MAP, tend to be more hydrophobic and Lastly, there has been recent interest in developing non-peptide mimics of CPPs. These 14 mimics of CPPs are typically built upon polymer backbones. By modifying the polymer side 15 chains an array of polymers have been synthesized that show robust transduction of cells. While 16 these non-peptide mimics of CPPs are not the focus of this paper, the interested reader is referred 17 to a recent review on the subject (Sgolastra et al. 2013 ). 18
Mechanism of Cellular Entry 19
From the beginning there has been considerable interest in exactly how CPPs enter cells. 20
The mechanisms are still not entirely understood, but what we are beginning to recognize is that 21 the mechanisms by which CPPs enter cells seems dependent on not only the type of CPP but also 22 its concentration (Brock 2014), the cargo that it transports, and the cell line on which it is being 23 tested. Arriving at this understanding has not been easy, as early studies provided contradictory 1 findings. As described above, Frankel and Pabo (1988) found that chloroquine enhanced the 2 uptake of Tat peptide, implying that an endocytic mechanism was likely. Vives, Brodin, and 3
Lebleu (1997), however, showed that the uptake of TAT occurred at 4 °C, which implied that 4 endocytosis was unlikely. In addition, the Prochiantz group showed that pAntp was also able to 5 enter cells at 4°C , thereby lending further evidence to an energy-independent, non-endosomal 6 uptake mechanism for CPPs (Derossi et al. 1994 ). The problem with these studies, and many 7 other early studies, was that they predominantly relied on fluorescence microscopy of fixed cells 8 or flow cytometry to measure uptake of CPPs. In 2002, it was shown that fixation of cells could 9 lead to artifactual redistribution of peptides that had otherwise simply been bound to the cell 10 membrane (Lundberg and Johansson 2002, Richard et al. 2003) . Both studies also showed that 11 despite extensive washing, cationic CPPs remained bound to the cell membrane, which could 12 erroneously lead one to conclude from flow cytometry that the CPPs had been internalized. 13
Taking into account the issues with flow cytometry and cell fixation, Richard et al. (2003) were 14 able to show that the uptake of the TAT peptide is indeed inhibited at 4 °C. Endosomal 15 distribution and the kinetics of uptake also helped confirm that TAT, under the conditions 16 described in the study, was internalized in an endocytic manner. 17 Figure 1 summarizes the different routes by which a CPP might enter a cell. While direct 18 translocation across the cell membrane occurs in some cases, it is generally accepted that most 19
CPPs and CPP-cargo complexes enter cells through endocytosis, including: macropinocytosis, 20
clathrin-mediated endocytosis, and caveolae/lipid raft-mediated endocytosis. Some CPPs have 21 been shown to use more than one of these internalization routes and to sometimes use different 22 routes simultaneously. Investigations into the TAT peptide, for example, have shown that TAT endocytosis. Further, they showed that increased membrane potential resulted in increased 10 cellular uptake of CPPs. 11
In addition to the models described here, there may be a newly discovered model that is not Understanding cellular internalization means not only studying the CPP complex as a 5
whole, but also considering the potential limitations of the different techniques used to study 6 internalization. One concern with many of the methods that have been used to study endocytosis 7 of CPPs is the use of chemical inhibitors. While chemical inhibitors can be used to help 8 understand the role of different endocytic uptake pathways in the internalization of CPPs, they 9
also have a substantial impact on cell viability, thereby significantly affecting cells in ways that 10 may make interpretation of the results difficult. Additionally, the performance of chemical 11 inhibitors can be highly dependent on the cell line used. Holm, Andaloussi, and Langel recently 12 wrote a book chapter describing several methods (including fluorescence microscopy, HPLC, 13 flow cytometry, spectrofluorometry, electron microscopy, and mass spectroscopy) for studying 14 the uptake of CPPs, which can avoid the use of chemical inhibitors (Holm et al. 2011). The 15
authors provide a list of the advantages and drawbacks associated with the different methods and 16 advocate for the use of more than one approach in order to avoid the negative aspects of the 17 different methods. 18
Applications using Cell-Penetrating Peptides 19
CPPs have been used in a wide number of applications, ranging from simple cell culture 20 transfection to the systemic delivery of therapeutics. The focus here is to highlight a few of the 21 many instances where CPPs have been used to deliver therapeutics, specifically nucleic acids, 22 proteins, small molecules, and imaging agents. Many of the examples of in vivo delivery are 23 limited to small animals, and application of CPPs to human therapeutics has yet to prove 1 effective. CPPs enhance the general uptake of a therapeutic but in doing so reduce the 2 specificity. This loss of specificity is not only likely to impact efficacy but also safety. Much of 3 the recent work has focused on using CPPs along with targeting ligands to improve delivery of a 4 therapeutic. As approaches to improve the targeted delivery of biomolecules are combined with 5
CPPs, therapeutics may be delivered more efficiently, thereby greatly improving treatment 6 outcomes. 7
Nucleic Acid Delivery 8
One of the first biomedical applications of CPPs was delivery of nucleic acids into cells. 9
As previously mentioned, large hydrophilic molecules, such as nucleic acids, are generally 10 inefficient at passing through the cell membrane. To improve the delivery of nucleic acids, 11 plasmid DNA has been complexed with cationic polymers or liposomes, which condense DNA CPPs seemed to improve the long-term gene expression from vectors that normally only provide 20 for very transient gene expression. One example of this was a TAT-PEI vector that extended the 21 gene expression period from about 1 month to nearly 7 months compared to TAT or PEI alone 22 The authors suggested that the multiple ligand approach increased the avidity for their siRNA 12 nanoparticles toward folate expressing cancer cells. these studies demonstrate that viral vectors can be modified to deliver genes to a much wider 9 range of targets, including various cancers and stem cells. In one study, TAT was shown to 10 increase the infectivity of an oncolytic adenovirus, which led to improved survival of tumor 11 can be an effective approach to control bacteria. Although many antimicrobial CPPs have been 21 discovered, the mechanism behind their broad penetration ability remains an area of active 22
investigation. In one recent study, Rodriguez et al. found that the membrane potential is a key 23 factor for cell entry of the model antimicrobial peptide Iztli-1 (Rodriguez Plaza et al. 2014) . This 1 provides a basis for further studies to understand why many CPPs can also act as antimicrobial 2 peptides. 3
Peptides, Proteins, and Enzymes 4
As with gene delivery, proteins are typically unable to passively enter cells. Because many CPPs have been incorporated also into gene editing strategies for treat disease. Specifically, 21
CPPs are being used to deliver endonucleases into cells as an approach to remove disease-22 causing genes. In one recent study, a CPP was used to deliver the Cas9 protein and guide RNA 1 for RNA-guided endonuclease gene editing (Ramakrishna et al. 2014) . Using this method, gene 2014) . The authors showed that the TALEN protein was able to specifically disrupt CCR5 and 5 BMPR1A genes. 6
As described in several earlier examples, CPPs make it possible to transport enzymes into 7 cells, which can lead to treatments for a wide range of diseases. Enzymes that prevent oxidative 8 damage are just one of several types of enzymes that are of interest for intracellular delivery, 9
which can lead to preventative treatments against ischemic injury. For example, TAT was 
Small Molecules 10
Similar to the large biomolecules discussed earlier, small hydrophilic molecules can also 11 face difficulties in traversing the hydrophobic cell membrane. In addition, diseases, conditions 12 such as cancer, can also prevent effective transport of small molecules across the lipid bilayer. 13
CPPs have been shown to be a practical approach in improving the delivery of small molecule 14 cytotoxic drugs into cancer cells, while reducing the exposure of non-diseased tissues. In one 15 study, doxorubicin was coupled with polyarginine and found to inhibit tumor growth in vivo with compound was found to improve the killing of cancer cells compared to the boron compound 17 without peptide. CPPs are also being used as part of innovative strategies to preserve cells 18 without cryopreservation. The preservation agent trehalose was delivered into cells using a 19 newly developed CPP, KRKRWHW, with the overall intent to investigate alternative cell 20 preservation by desiccation (Wei et al. 2014) . The authors demonstrate that the novel CPP enters 21 cells and that the inclusion of the preservation agent is non-toxic. Another example of delivery 22 of a small molecule using CPPs is the conjugation of the Tat CPP to a fluorescent label to 23 1 of a strategy to damage the lipid membrane upon excitation of the label. 2
Novel chemotherapy approaches have focused on limiting the activity of anticancer drug-3 CPP conjugates to tumor tissue. One approach that is growing in popularity is to make the CPP 4 functional only when an enzyme common to the extracellular environment of tumors is present. 
Imaging 15
Imaging is of growing importance in the detection and monitoring of disease markers, 16
which can lead to more effective disease management. CPPs have been coupled with 17 fluorophores, contrast agents, quantum dots, and other readily detectable molecules for 18 visualizing the intracellular environment as well as specific cells comprising a tissue. In fact, 19
fluorophores were one of the earliest cargos conjugated to CPPs as a means to study their activity. 20
Since then, CPPs have become important tools in biology for delivering fluorophores and 21 quantum dots for intracellular detection. Earlier studies, such as that by Delehanty et al., 22 demonstrated that quantum dots could be transported across the lipid bilayer using polyarginine 1 (Delehanty et al. 2006) . Subsequent work has utilized CPPs to deliver fluorescent agents into 2 cells for targeted intracellular delivery, which has also proven to be especially useful in cell these probes allowed for the study of oxygen use inside cells. New fluorescence strategies using 7
CPPs have also been developed for better diagnosis of diseases over-expressing certain 8
intracellular markers, such as the ubiquitin E3 ligase Smurf1 (Suh et al. 2014) . Researchers were 9
able to observe Smurf1 binding through a CPP bearing a FITC label, a black hole quencher, and 10 a Smurf1 binding peptide. Changes in peptide confirmation with binding allowed for the group 11 to observe the peptide and protein binding. 12
CPPs have been designed to activate in certain tissue environments, and this has led to 13 several exciting imaging applications. For example, there is great interest in developing CPPs 14 that will activate in tumors, which can in turn improve the detection of cancer cells and allow for 15 real time imaging so that tumors may be removed more effectively. CPP fluorophore conjugates 16
have been designed to become active in tumors through an anionic domain that may be removed 17 by tumor matrix metalloproteinases, effectively labeling tumor cells (Jiang et al. 2004 (Savariar et al. 2013) . In this study, a tumor specific protease disrupts the quenching of a 22 label when the CPP is activated, which results in ratiometric detection of tumor metastasis. This 23 approach has also been used for detection of thrombin activation in which a CPP was made 1 active by thrombin, allowing the CPP to be internalized in nearby cells, which can lead to better 2 treatment of atherosclerosis and strokes (Whitney et al. 2013 ). Another exciting approach has 3 been the development of chemically sensitive linkers to produce other novel activatable CPPs. 4
This has led to new possibilities of detecting chemicals through imaging. For example, 5
Weinstain et al., developed a hydrogen peroxide activatable CPP to observe inflammation in the 6 lungs of mice using FRET (Weinstain et al. 2013 ). This enabled the group to detect oxidative 7 stress both in vitro and in vivo, which has the potential to be a useful tool to monitor several 8 types of diseases. 9
Conclusions 10
CPPs offer an exciting potential to transport many different types of therapeutic drugs 11 across the cell membrane and into cellular compartments or the cell cytoplasm where a drug can 12 be most effective. While we do not entirely understand nor can we necessarily predict how a 13 CPP and its cargo will be transported into cells, we are developing the tools and knowledge 14 necessary to harness their ability. Already, there are hundreds of CPPs being explored for the 15 delivery of therapeutic small molecules, peptides, proteins, nucleic acids, and imaging agents. 
